Mayo Clinic and Orion to Validate Breast Cancer Biomarkers | GenomeWeb
This correction clarifies that the alliance is to validate, not identify, breast cancer biomarkers.
 
NEW YORK (GenomeWeb News) — Orion Genomics will work with researchers at the Mayo Clinic to validate the company’s breast cancer screening technology in a clinical environment.
 
Orion will use its epigenetic biomarker-based technology with physicians at Mayo Clinic’s Department of Laboratory Medicine and Pathology to analyze cross-reactivity in more than a dozen types of breast cancer.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The White House has created a list of cuts, including to the NIH, that could be in a budget bill for this year.

The US National Institutes of Health is to allow applicants to cite preprints just as they would any other research paper, ScienceInsider reports.

Two manuscript pages handwritten by Charles Darwin are going on the auction block, according to the Los Angeles Times.

In PNAS this week: tool to track transcriptome-wide binding, evidence of balancing selection on behavior-linked genes, and more.